A new study combined the results of prior studies of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and an inherited gene mutation through a meta-analysis. The results showed that PARP inhibitors provided the greatest benefit in BRCA1/2 carriers and there was a strong signal of benefit in PALB2 or CDK12 alterations. However, there was no benefit observed in those with ATM or CHEK2 alterations.
Naqvi, et al. Eur Urol. 2025;87(6):626-640. PMID: 39848867. Article available at: https://pubmed.ncbi.nlm.nih.gov/39848867/. Social media post available at: https://www.facebook.com/share/p/1EaQ3dKG3H/